B
Biolevate
Agentic AI for auditable scientific and regulatory life-sciences workflows
About Biolevate
Biolevate is a Paris life-sciences AI company founded by former Dataiku engineers and AI researchers, including co-founder and CEO Joël Belafa. It builds an enterprise agentic AI platform that turns scientific and regulatory knowledge into auditable, evidence-grounded workflows so pharmaceutical, MedTech and healthcare organisations can automate work across research, clinical trials, health-technology assessments, regulatory dossiers, drug discovery and development while keeping human oversight. The platform can run large numbers of concurrent agents and has reported large efficiency gains on systematic literature reviews and regulatory intelligence. After a 2024 seed, Biolevate serves more than a dozen enterprise customers, has expanded ARR, drafted multiple patent applications and is opening a Boston office. In September 2026 it raised a €30 million Series A co-led by RAISE France and Orange Ventures, with MSD Global Health Innovation Fund (MGHIF), Station F and existing investor EQT Ventures, to deepen product capabilities, scale deployments and accelerate international growth. Sources: Tech.eu 22 Sep 2026; biolevate.com.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2024
- Headquarters
- Paris, France
- Employees
- 36
- Open positions
- 8
- Dealroom signal
- 87.1/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Medical Education, Clinical, Clinical Decision Support, Physician Support Tools, AI Drug Discovery, biotech medtech and e-health, Observatoire Deeptech
- Technology
- Artificial Intelligence
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Nov 2024 | $6.6M | $26M | Bpifrance · Mehdi Ghissassi · EQT Ventures | ↗ |
Growth signals
Latest recorded traffic for Biolevate is 4.3K monthly website visits, up 207.1% over the last three months. Biolevate's team grew 24.1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
EQT Ventures
Bpifrance- MGMehdi Ghissassi
Other known investors1 additional known investor
Future4Care
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Biolevate on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Biolevate’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.